Dishman Pharma is currently in talks for $100-200m for its contract research and manufacturing business. Managing director, JR Vyas, puts this down to pharma companies exiting API manufacturing. Dishman is seeking an Asian acquisition to establish Carbogen Amcis as a full-service oncology package provider.
Money Control
Tuesday 26 August 2008
Dishman looks to $200m manufacturing contracts and acquisition
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment